Report Overview

According to the deep-dive market assessment study by Growth+ Reports, the Global Heart Blocks Treatment Market was valued at US$ 5.2 billion in 2021. The market is expected to witness a CAGR of 4% from 2022 to 2030.

Market Fundamentals

Heart block is also called atrioventricular (AV) block, it occurs when there is a problem with the heart's electrical system in which the electrical signal that controls the heartbeats is completely or partially blocked. This causes the heart to beat slowly or miss beats, making the heart unable to pump blood efficiently. Depending on the severity of the electrical signal disruption, a heart block may be categorized in first degree, second degree, or third-degree blocks. The heart block treatment depends on the type, severity, and symptoms. Based on the symptoms, a pacemaker may be required to keep the heart beating. A pacemaker is a small device that sends electrical pulse and impulses to the heart.

[878869]

Market Dynamics 

The increasing prevalence of cardiovascular diseases and the rise in the geriatric population globally are the major driving factor of the global heart blocks treatment market. The rising demand for minimally invasive cardiac procedures over open surgeries due to the reduced hospital stay duration, lesser risk of infection & bleeding, and faster recovery is also playing a pivotal role in the growth of the global market. Moreover, there is a rise in the adoption of advanced technologies such as AI to improve the pacemaker. The rise in the unhealthy lifestyle, obesity, and lack of physical activity also increase the chances of heart disease. However, the cost of the heart block products is high and thus is a major restricting factor of the global heart blocks treatment market. Additionally, the limited awareness of heart block diseases, lack of advanced technology, and unfavorable insurance policy in developing countries is also hampering the global market growth. 

Market Ecosystem

The global heart blocks treatment market has been analyzed from three perspectives: type, treatment, and region. 

Heart Blocks Treatment Market by Type 

[454323]

Based on type, the global heart blocks treatment market is segmented into first-degree heart blocks, second-degree heart blocks, and third-degree heart blocks. The first-degree heart blocks segment have the largest market share of the global heart blocks treatment market in 2021. The large share of the first-degree heart blocks segment can be attributed to the rise in the aged population with unhealthy lifestyle and obesity. Moreover, there is a rise in the number of people living with heart conditions as they are more prone to first-degree heart block. According to the British Heart Foundation, around 550 million people are living with heart diseases worldwide. Additionally, the first-degree block is also commonly observed in athletes, teenagers, young adults, and people with high active vagus nerve, thus increasing the demand for the first-degree heart block treatment. 

Heart Blocks Treatment Market by Treatment

Based on treatment, the global heart blocks treatment market is segmented into pacemaker, transcutaneous pacing (TCP), medication, and follow-up electrophysiology study. The Pacemaker segment dominated the global heart block treatment market with the largest share in 2021. The rise in the prevalence of cardiovascular diseases, which requires pacemakers such as atrial fibrillation, and the rising demand for minimally invasive procedures are playing a pivotal role in segment growth. Moreover, a rise in the pacemaker procedures is also propelling the segment growth. According to the National Center for Biotechnology Information, around one million pacemakers are placed every year globally. The adoption of advanced technologies and a rise in the research related to pacemakers making more compact devices is also boosting demand. 

Heart Blocks Treatment Market by Region

Based on region, the global heart blocks treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global heart blocks treatment market in 2021, followed by Europe. Asia Pacific market is anticipated to grow at the fastest CAGR during the forecast period. The large share of North America can be attributed to the rise in the prevalence of cardiovascular diseases and the the rising geriatric population. Moreover, the rising demand for minimally invasive procedures and the increase in the pacemaker procedures are also propelling the regional market growth. The presence of well-developed healthcare infrastructure, good reimbursement policy, and rise in the awareness regarding CVDs in the region is also boosting the growth. 

Competitive Landscape

Some of the prominent players operating in the global heart blocks treatment market are:

• Boston Scientific Corporation
• Medtronic Plc
• Abbott Laboratories
• BIOTRONIK SE & Co. KG
• SORIN S.p.A
• Edward Lifesciences Corporation
• Novartis AG
• Pfizer Inc.
• Gilead Sciences Inc.
• Janssen Pharmaceuticals Inc.
• Sanofi S.A.
• Merck & Co Inc.
• Koninklijke Philips N.V.
• Bayer AG
• F. Hoffmann-La Roche AG
• Natco Pharma

Strategic Developments

• In April 2022, Bristol Myers Squibb received approval for its Mavacamten drug from FDA which is an oral drug. It helps in treating hypertrophic cardiomyopathy, a genetic heart disease that leads to sudden cardiac arrests.
• In February 2022, Abbott announced the world’s first implantation of dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study. This technology allows to regulate the heart rate synchronously between chambers and true dual-chamber leadless pacing.

Frequently Asked Questions About This Report